Calidi Biotherapeutics, Inc. (CLDI) Revenue History
Annual and quarterly revenue from 2020 to present
CLDI Revenue Over Time (2020–2024)
CLDI Revenue Growth History
0 of 2 years with positive growth- FY2020 revenue growth
- N/A
- FY2021 revenue growth
- N/A
- FY2022 revenue growth
- -90.0%
- FY2023 revenue growth
- -100.0%
- FY2024 revenue growth
- N/A
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2025 | $0 | — |
| Q2 2025 | $0 | — |
| Q1 2025 | $0 | — |
| Q4 2024 | $0 | — |
| Q3 2024 | $0 | — |
| Q2 2024 | $0 | — |
| Q1 2024 | $0 | — |
| Q4 2023 | $0 | — |
Multi-year avg. share of annual revenue by fiscal quarter
CLDI Revenue Analysis (2020–2024)
Current Revenue & Growth
As of June 22, 2026, Calidi Biotherapeutics, Inc. (CLDI) generated trailing twelve-month (TTM) revenue of $0. The most recent quarter (Q3 2025) recorded $0 in revenue
Historical Growth Trajectory
CLDI's historical revenue data shows various trends over time. Calidi Biotherapeutics, Inc.'s highest annual revenue of $449,000 was recorded in 2021.
Peer Comparison
Compared to Healthcare sector peers — including TGTX (+81.3% YoY), CGEN (+870.2% YoY), and VVOS (+33.8% YoY). Compare CLDI vs TGTX →
CLDI Revenue vs Peers
Revenue metrics vs comparable public companies
| Company | TTM Revenue | YoY Growth | 5Y CAGR | Op. Margin | Compare |
|---|---|---|---|---|---|
| CLDICurrent | $0 | - | - | - | |
 TGTX | $616M | +81.3% | +426.7% | 20.0% | |
 CGEN | $73M | +870.2% | +105.2% | 43.1% | |
 VVOS | $17M | +33.8% | +5.9% | -114.1% |
CLDI Historical Revenue Data (2020–2024)
| Year | Revenue | YoY % | Gross Profit | Gross Margin | Op. Income | Op. Margin |
|---|---|---|---|---|---|---|
| 2024 | $0 | - | $0 | - | $-21,776,000 | - |
| 2023 | $0 | -100.0% | $-1,256,000 | - | $-28,992,000 | - |
| 2022 | $45K | -90.0% | $-229,000 | -508.9% | $-23,128,000 | -51395.6% |
| 2021 | $449K | - | $355K | 79.1% | $-10,482,000 | -2334.5% |
| 2020 | $0 | - | $0 | - | $-6,773,000 | - |
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Historical Returns
6+ years return with dividends reinvested.
DCA Calculator
See how regular investing compounds over time.
Peer Comparison
Compare growth, multiples, and margins vs sector.
CLDI — Frequently Asked Questions
Quick answers to the most common questions about buying CLDI stock.
Is CLDI's revenue growth accelerating or slowing?
CLDI TTM revenue: $0.00. YoY growth: N/A. 5-year CAGR: N/A.
What is CLDI's revenue history from 2020 to 2026?
Calidi Biotherapeutics, Inc. (CLDI) revenue history spans 2020 to 2026. TTM revenue as of 2026 is $0.00, growing at N/A YoY. The 5-year CAGR is N/A. Complete annual and quarterly revenue figures are available on this page, including gross profit, operating income, and margin trends.
What is CLDI's long-term revenue growth rate (CAGR)?
Calidi Biotherapeutics, Inc.'s 5-year revenue CAGR of N/A reflects the variable nature of its business expansion. As of 2026, the current YoY growth rate of N/A is in line with this long-term average. CAGR is the most reliable measure of sustained revenue momentum for CLDI.
Why does CLDI's quarterly revenue fluctuate?
CLDI quarterly revenue can fluctuate significantly between periods. A quarter-over-quarter (QoQ) change does not always indicate a trend; comparing the same quarter year-over-year (YoY) is a more reliable signal for underlying growth. Calidi Biotherapeutics, Inc.'s revenue data from 2020 to 2026 shows full historical quarterly detail on this page.
How is CLDI's revenue distributed by segment?
CLDI reports revenue broken down by product line and geographic region. The segment breakdown on this page shows which business units contribute the most to total revenue as of the latest fiscal year. Concentration in a single segment above 50% indicates category dependence, while a diversified mix signals more resilient revenue streams.
How does CLDI's revenue compare to industry peers?
Calidi Biotherapeutics, Inc. (CLDI) with TTM revenue of $0.00 and N/A YoY growth can be benchmarked against sector peers using the comparison table on this page. Revenue growth relative to peers indicates market share gains or losses. The peer section shows TTM revenue, YoY growth, and operating margin for direct comparisons.